Literature DB >> 33671865

The Interrelationships between Intestinal Permeability and Phlegm Syndrome and Therapeutic Potential of Some Medicinal Herbs.

Junghyun Park1,2, Tae Joon Choi2,3, Ki Sung Kang1, Seo-Hyung Choi4.   

Abstract

The gastrointestinal (GI) tract has an intriguing and critical role beyond digestion in both modern and complementary and alternative medicine (CAM), as demonstrated by its link with the immune system. In this review, we attempted to explore the interrelationships between increased GI permeability and phlegm, an important pathological factor in CAM, syndrome, and therapeutic herbs for two disorders. The leaky gut and phlegm syndromes look considerably similar with respect to related symptoms, diseases, and suitable herbal treatment agents, including phytochemicals even though limitations to compare exist. Phlegm may be spread throughout the body along with other pathogens via the disruption of the GI barrier to cause several diseases sharing some parts of symptoms, diseases, and mechanisms with leaky gut syndrome. Both syndromes are related to inflammation and gut microbiota compositions. Well-designed future research should be conducted to verify the interrelationships for evidence based integrative medicine to contribute to the promotion of public health. In addition, systems biology approaches should be adopted to explore the complex synergistic effects of herbal medicine and phytochemicals on conditions associated with phlegm and leaky gut syndromes.

Entities:  

Keywords:  gut microbiome; increased GI barrier permeability; inflammation; medicinal plants; phlegm syndrome; phytochemicals

Year:  2021        PMID: 33671865      PMCID: PMC7918952          DOI: 10.3390/biom11020284

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  118 in total

Review 1.  Gut reactions: How the blood-brain barrier connects the microbiome and the brain.

Authors:  Aric F Logsdon; Michelle A Erickson; Elizabeth M Rhea; Therese S Salameh; William A Banks
Journal:  Exp Biol Med (Maywood)       Date:  2017-11-23

Review 2.  The interaction between the gut Microbiota and herbal medicines.

Authors:  Xuedong An; Qi Bao; Sha Di; Yiru Zhao; Shenghui Zhao; Haiyu Zhang; Fengmei Lian; Xiaolin Tong
Journal:  Biomed Pharmacother       Date:  2019-08-23       Impact factor: 6.529

Review 3.  Mechanisms of inflammation-driven bacterial dysbiosis in the gut.

Authors:  M Y Zeng; N Inohara; G Nuñez
Journal:  Mucosal Immunol       Date:  2016-08-24       Impact factor: 7.313

4.  Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome.

Authors:  Robert J Shulman; Monica E Jarrett; Kevin C Cain; Elizabeth K Broussard; Margaret M Heitkemper
Journal:  J Gastroenterol       Date:  2014-01-17       Impact factor: 7.527

5.  Asthma, hay fever, and phlegm production associated with distinct patterns of allergy skin test reactivity, eosinophilia, and serum IgE levels. The Normative Aging Study.

Authors:  D J Tollerud; G T O'Connor; D Sparrow; S T Weiss
Journal:  Am Rev Respir Dis       Date:  1991-10

6.  Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.

Authors:  Patrice D Cani; Rodrigo Bibiloni; Claude Knauf; Aurélie Waget; Audrey M Neyrinck; Nathalie M Delzenne; Rémy Burcelin
Journal:  Diabetes       Date:  2008-02-27       Impact factor: 9.461

7.  Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-κB pathway.

Authors:  Cailan Li; Gaoxiang Ai; Yongfu Wang; Qiang Lu; Chaodan Luo; Lihua Tan; Guosheng Lin; Yuhong Liu; Yucui Li; Huifang Zeng; Jiannan Chen; Zhixiu Lin; Yanfang Xian; Xiaoqi Huang; Jianhui Xie; Ziren Su
Journal:  Pharmacol Res       Date:  2019-12-19       Impact factor: 7.658

8.  [Establishment and Evaluation of Hypertensive Rat Model with Excessive Accumulation of Phlegm-dampness Syndrome].

Authors:  Sai Wu; Yue-hua Jiang; Chuan-hua Yang; Xian-qing Meng; Dong Hao; Ying-zi Qi
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2016-02

9.  Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease.

Authors:  Kelly A Shaw; Madeline Bertha; Tatyana Hofmekler; Pankaj Chopra; Tommi Vatanen; Abhiram Srivatsa; Jarod Prince; Archana Kumar; Cary Sauer; Michael E Zwick; Glen A Satten; Aleksandar D Kostic; Jennifer G Mulle; Ramnik J Xavier; Subra Kugathasan
Journal:  Genome Med       Date:  2016-07-13       Impact factor: 11.117

10.  Xuan Bai Cheng Qi formula as an adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease of the syndrome type phlegm-heat obstructing the lungs: a multicenter, randomized, double-blind, placebo-controlled clinical trial.

Authors:  Miao Liu; Xianggen Zhong; Yuhang Li; Fengjie Zheng; Ruohan Wu; Yan Sun; Jinchao Zhang
Journal:  BMC Complement Altern Med       Date:  2014-07-11       Impact factor: 3.659

View more
  1 in total

1.  Phytochemical Constituents of Medicinal Plants for the Treatment of Chronic Inflammation.

Authors:  Ki Sung Kang
Journal:  Biomolecules       Date:  2021-04-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.